PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 18, 2026Journal of the European Academy of Dermatology and Venereology

Systematic review and network meta‐analysis of biologics and small molecules for scalp psoriasis

View Full Paper
Ask AI
Bookmark
Share

Authors

ILI‐Chang LaiKLKuan-Chun LeeGHGuan‐Lun Huang

Discussion

Loading...

Member takes

Overview

Systematic review analyzes effectiveness and safety of scalp psoriasis treatments, implying guidance for therapy choice.

Key Points

  • To compare the short-term efficacy, safety, and tolerability of biologics and small molecules for scalp psoriasis.
  • Conducted a systematic review and network meta-analysis of randomized controlled trials (RCTs)
  • Included 16 RCTs with 10,266 patients from various databases until October 2025
  • Primary endpoint was scalp clearance at Weeks 12-16, evaluated through multiple scales.
  • All active agents showed statistically significant improvements versus placebo.
  • Ixekizumab Q2W had the highest OR (54.02; 95% CI 39.38-74.09) for scalp clearance, followed by brodalumab.
  • Apremilast had a significantly higher discontinuation rate due to AEs (OR 1.62; 95% CI 1.09-2.42).

Cite This Study

Lai et al. (2026) studied this question.

synapsesocial.com/papers/6a0aad145ba8ef6d83b708e8https://doi.org/10.1111/jdv.70506
View Full Paper
Ask AI
Bookmark
Share